Marc Dror Michaelson
Harvard University · 301 works · 28,938 citations · h-index 65
Top works
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
- Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- Kidney Cancer
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)
- Sunitinib Efficacy Against Advanced Renal Cell Carcinoma
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients
- Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
- Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience